32 month follow-up of mountaineer: tucatinib and trastuzumab in her2 mcrc
Published 3 months ago • 59 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:14
updated analysis from mountaineer: tucatinib and trastuzumab for her2-positive mcrc
-
2:29
mountaineer: tucatinib plus trastuzumab for her2 metastatic colorectal cancer
-
0:56
mountaineer results: trastuzumab and tucatinib for her2 mcrc
-
1:24
tucatinib and trastuzumab in the treatment paradigm of her2-positive mcrc
-
2:28
mountaineer: impact of genomic alterations on tucatinib plus trastuzumab activity in mcrc
-
4:46
mountaineer: tucatinib in combination with trastuzumab for her2-positive metastatic colorectal c...
-
0:58
mountaineer: clinical relevance of genomic profiling for tucatinib trastuzumab treatment in mcrc
-
0:43
how will the mountaineer trial affect the her2-positive mcrc treatment landscape?
-
0:47
mountaineer-03: tucatinib plus trastuzumab plus folfox for first-line treatment of mcrc
-
17:40
mountaineer study lead to the tucatinib/trastuzumab fda approval - in discussion w/ dr. bekaii-saab
-
1:19
targeted therapies for patients with her2 colorectal cancer
-
2:23
mountaineer-02: tucatinib in previously treated her2 gastric cancer
-
1:01
dr. bekaii-saab on safety profile of tucatinib/trastuzumab in her2 amplified mcrc
-
1:47
her2climb-05: tucatinib trastuzumab and pertuzumab as maintenance therapy for her2 metastatic bc
-
1:42
dr. bekaii-saab on the rationale to explore tucatinib/trastuzumab in her2-overexpressing mcrc
-
1:14:00
twiv 602: coronavirus immunology with stanley perlman
-
1:25
real-world treatment patterns for her2-amplified colorectal cancer
-
31:17
molecular testing and the role of her2 in managing advanced colorectal cancer
-
36:12
her2-positive metastatic colorectal cancer: unraveling game-changing treatment approaches